Commercial-stage Chinese biotech developing small molecule inhibitors for cancer.
Industry: Health Care
Latest Trade: $17.26 0.00 (0.0%)
First Day Return: +0.8%
Return from IPO: +0.1%
Industry: Health Care
IPO Data | |
---|---|
IPO File Date | 12/27/2024 |
Offer Price | $17.25 |
Price Range $17.25 - $17.25 | |
Offer Shares (mm) | 7.3 |
Deal Size ($mm) | $126 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
IPO Data | |
---|---|
IPO Date | 01/23/2025 |
Offer Price | $17.25 |
Price Range $17.25 - $17.25 | |
Offer Shares (mm) | 7.3 |
Deal Size ($mm) | $126 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
Underwriters |
---|
J.P. Morgan |
Citi |
Company Data | |
---|---|
Headquarters | Suzhou, China |
Founded | 2009 |
Employees at IPO | 600 |
Website www.ascentage.com |